Viatris to sell Biocon Biologics stake for $815 million Dec 8, 2025 02:55AM
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited Dec 6, 2025 09:00AM
Viatris Inc (VTRS) Announces the Pricing Terms of Maximum Tender Offer Sep 18, 2024 11:34AM
Viatris Announces the Pricing Terms of Maximum Tender Offer Sep 18, 2024 11:30AM
Viatris Announces Early Tender Results and Increase of Pending Maximum Tender Offer Sep 17, 2024 08:45PM


Sep 10, 2024 07:00PM Viatris Announces Expiration and Results of Any and All Cash Tender Offers
Sep 10, 2024 11:40AM Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers
Sep 4, 2024 03:30AM Viatris Announces Cash Tender Offers for Certain Outstanding Notes
Feb 28, 2024 05:55AM Viatris Inc (VTRS) and Idorsia Enter Global Research and Development Collaboration
Feb 28, 2024 01:00AM Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
Dec 15, 2023 04:45PM Viatris Inc (VTRS) Appoints Doretta Mistras as CFO, Philippe Martin as Chief R&D Officer
Dec 15, 2023 04:45PM Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Phil
Nov 7, 2022 08:02AM Oyster Point Pharma Inc. (OYST) to be Acquired by Viatris (VTRS) for $11 Per Share Plus CVR
Nov 7, 2022 08:00AM Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
Nov 7, 2022 08:00AM Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
Aug 30, 2021 08:00AM Viatris Inc. to Participate in Citi's 16th Annual BioPharma Conference
Jun 16, 2021 06:40AM Citi Starts Viatris (VTRS) at Neutral